Physician profile
Brian C Smith
NPI 1790377075
$9,507.44
in general payments reported to CMS, 2019-2025
25 companies · $2,116 in 2025
The $2,116 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $1,671 · 2023: $2,833 · 2024: $2,593 · 2025: $2,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,438 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,438.12 |
| Education | $103.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,816.55 | 2022-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $1,110.11 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Axsome Therapeutics, INC. | $906.91 | 2022-2025 | Auvelity |
| Abbvie INC. | $891.12 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $628.50 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alkermes, INC. | $547.56 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $490.66 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $464.03 | 2021-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $436.07 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $413.09 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $392.74 | 2024-2025 | Cobenfy |
| Corium, LLC | $288.32 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $192.47 | 2021-2024 | Trintellix |
| Pfizer INC. | $168.55 | 2023 | |
| Lundbeck LLC | $146.53 | 2021-2025 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $137.21 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.24 | 2022 | |
| Avanir Pharmaceuticals, INC. | $63.56 | 2022 | |
| Merck Sharp & Dohme LLC | $57.79 | 2022-2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $43.04 | 2025 | Fanapt |
| Almatica Pharma LLC | $42.87 | 2021 | |
| Ironshore Pharmaceuticals INC. | $40.94 | 2023-2024 | Jornay Pm |
| Kite Pharma, INC. | $32.21 | 2023 | Yescarta |
| Idorsia Pharmaceuticals US INC | $32.12 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $28.25 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.